Silencing of lncRNA MALAT1 inhibits cell cycle progression via androgen receptor signaling in prostate cancer cells

被引:30
作者
Dai, Xiaofan [1 ]
Liu, Lingyun [1 ]
Liang, Zuowen [2 ]
Guo, Kaimin [1 ]
Xu, Shengqi [1 ]
Wang, Hongliang [1 ]
机构
[1] Jilin Univ, Hosp 1, Dept Androl, 71 Xinmin Ave, Changchun 130021, Jilin, Peoples R China
[2] Jilin Univ, Hosp 1, Human Sperm Bank Jilin Prov, Changchun 130021, Jilin, Peoples R China
关键词
Metastasis associated lung adenocarcinoma transcript 1; Prostate cancer; Androgen receptor; Long noncoding RNA; microRNA; LONG NONCODING RNAS; RESISTANCE; PROLIFERATION; METASTASIS; SUPPRESSES;
D O I
10.1016/j.prp.2019.01.011
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Prostate cancer is the second common cancer in men with high morbidity and mortality. Androgen receptor (AR) signaling plays a crucial role in occurrence and development of prostate cancer. In this study, we demonstrated that lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was increased in prostate cancer cells after androgen stimulation, as well as AR. The silencing of MALAT1 inhibited dihydrotestosterone (DHT) administration-induced acceleration of proliferation and cell cycle progression, and increase of AR expression in prostate cancer cells. MALAT1 bound to miR-320b and negatively regulated its expression, and vice versa. AR is a target of miR-320b. The phenotypic changes induced by silencing of MALAT1 were abolished by miR-320b inhibition or AR overexpression. Additionally, MALAT1 knockdown also suppressed the tumorigenesis of prostate cancer cells in nude mice. In summary, the silencing of MALAT1 inactivated AR signaling by sponging miR-320b, and inhibited proliferation and cell cycle progression in prostate cancer cells, suggesting that MALAT1 may be a new target in diagnosis and therapy of prostate cancer in clinic.
引用
收藏
页码:712 / 721
页数:10
相关论文
共 32 条
  • [1] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [2] Prostate cancer
    Attard, Gerhardt
    Parker, Chris
    Eeles, Ros A.
    Schroder, Fritz
    Tomlins, Scott A.
    Tannock, Ian
    Drake, Charles G.
    de Bono, Johann S.
    [J]. LANCET, 2016, 387 (10013) : 70 - 82
  • [3] Long Noncoding RNAs: Cellular Address Codes in Development and Disease
    Batista, Pedro J.
    Chang, Howard Y.
    [J]. CELL, 2013, 152 (06) : 1298 - 1307
  • [4] MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma
    Boll, K.
    Reiche, K.
    Kasack, K.
    Moerbt, N.
    Kretzschmar, A. K.
    Tomm, J. M.
    Verhaegh, G.
    Schalken, J.
    von Bergen, M.
    Horn, F.
    Hackermueller, J.
    [J]. ONCOGENE, 2013, 32 (03) : 277 - 285
  • [5] The long and the short of noncoding RNAs
    Brosnan, Christopher A.
    Voinnet, Olivier
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2009, 21 (03) : 416 - 425
  • [6] Bussemakers MJG, 1999, CANCER RES, V59, P5975
  • [7] Molecular determinants of resistance to antiandrogen therapy
    Chen, CD
    Welsbie, DS
    Tran, C
    Baek, SH
    Chen, R
    Vessella, R
    Rosenfeld, MG
    Sawyers, CL
    [J]. NATURE MEDICINE, 2004, 10 (01) : 33 - 39
  • [8] A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
    Craft, N
    Shostak, Y
    Carey, M
    Sawyers, CL
    [J]. NATURE MEDICINE, 1999, 5 (03) : 280 - 285
  • [9] Androgen receptor cross-talk with cell signalling pathways
    Culig, Z
    [J]. GROWTH FACTORS, 2004, 22 (03) : 179 - 184
  • [10] Long Noncoding RNAs in Cell-Fate Programming and Reprogramming
    Flynn, Ryan A.
    Chang, Howard Y.
    [J]. CELL STEM CELL, 2014, 14 (06) : 752 - 761